Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IVS-020
- Development stage
- Preclinical
- Lead developer
- Invivoscribe
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IVS-020 is a preclinical small molecule program in-licensed by Invivoscribe from Domainex. It is being developed as an oral immunotherapy agent intended to treat hematological malignancies, including acute myeloid leukemia. Invivoscribe plans to leverage its diagnostics expertise and global network for the drug's development and commercialization.
Beyond the preview
Go deeper on IVS-020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IVS-020.